UBS's Wealthiest Clients Are Quietly Moving Billions -- Here's Where It's Going
UBS's (NYSE:UBS) wealthiest clients are quietly steering their portfolios toward alternative investments a move that could reshape how high-net-worth capital flows in a jittery macro environment. According to Iqbal Khan, co-president of global wealth management and head of UBS Asia Pacific, there's a growing tilt toward assets like private equity, hedge funds, and real estate. Speaking at the UBS Asian Investment Conference in Hong Kong, Khan said the shift is still in its early innings, but momentum is building. We've definitely seen significant growth, he said, noting that alternatives still make up a small slice of most client portfolios meaning there could be plenty of room to run.
Warning! GuruFocus has detected 2 Warning Sign with UBS.
The backdrop? Volatility, geopolitical friction, and rate-cut guessing games. UBS's markets unit just booked a record quarter off that volatility. Meanwhile, clients are bracing for a possible stagflation setup and looking for stability outside traditional equities and bonds. Khan, who moved to Hong Kong in 2024 to take on the top Asia role, added that rate cuts could be coming, but the timeline remains fluid. For UBS, this moment isn't just about investment advice it's about playing offense as rivals like HSBC and DBS step up in Asia. UBS remains the region's dominant wealth player, backed by over 900 advisers.
Behind the scenes, the firm is still digesting its 2023 Credit Suisse takeover and slashing deep to make it work. UBS has already axed 10,000+ jobs and locked in $7.5 billion in cost savings on the way to its $13 billion goal. But it's also facing a tense debate with Swiss regulators over how much capital it should hold to brace for the next crisis. All of this could come to a head sooner than expected. CEO Sergio Ermotti is expected to step down by early 2027, and both Khan and U.S. private banking chief Rob Karofsky are seen as top contenders to take the reins.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
2 hours ago
- Wall Street Journal
Novartis's Cancer Treatment Pluvicto Shows Positive Results in Trial
Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed statistically significant and clinically meaningful benefits—including combined with hormone therapy versus hormone therapy alone—with positive trend in overall survival.
Business Wire
2 hours ago
- Business Wire
Lazard Opens New UK Headquarters in Historic Manchester Square, W1
LONDON--(BUSINESS WIRE)--Lazard, Inc. (NYSE: LAZ) announced today that its new UK headquarters opened at 20 Manchester Square, housing both the firm's Financial Advisory and Asset Management businesses. The new, larger office reflects Lazard's commitment to London as one of the world's leading financial centres and the firm's continued growth in Europe. 20 Manchester Square will become part of Lazard's European footprint and one of its three main global offices, alongside New York and Paris. As a cornerstone of Lazard's international network, the new UK HQ extends the firm's long-standing presence in London which dates back to 1877. Cyrus Kapadia, Co-Head of European Investment Banking and CEO of UK Financial Advisory, said: "The move to 20 Manchester Square underscores our unwavering commitment to the UK and our deep-rooted heritage in London. We have been successfully growing our European teams and network to further support our clients across Europe and around the globe." Jeremy Taylor, CEO of Lazard UK Asset Management said, '20 Manchester Square is more than just a new office—it's a reflection of our values and vision. We are committed to delivering exceptional performance for our clients. This new UK headquarters embodies our dedication to innovation, collaboration, and thoughtful stewardship as we continue to best serve the needs of our clients.' The new building offers modern office space and has been designed with an emphasis on innovation and sustainable standards of construction, technology and use. The space has renewable energy from solar panels on the roof and a rainwater harvesting system. The building's construction adhered to the UK Green Building Council framework for net-zero carbon emissions and recycled, long-life materials with reduced replaceability have been used across floors, walls and ceiling finishes, with water efficient taps, showers and fixtures in place throughout. 20 Manchester Square is situated next door to the Wallace Collection and Regent's Park, and the area is well known for its cultural landmarks and accessible transport links. Lazard UK is relocating from 50 Stratton Street, after over twenty years. ABOUT LAZARD Founded in 1848, Lazard is the preeminent financial advisory and asset management firm, with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. For more information, please visit and follow Lazard on LinkedIn.
Business Insider
2 hours ago
- Business Insider
Bernstein Keeps Their Hold Rating on Pfizer (PFE)
Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $30.00. Confident Investing Starts Here: Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Pfizer, and Moderna. According to TipRanks, Breen has an average return of -0.1% and a 27.78% success rate on recommended stocks. In addition to Bernstein, Pfizer also received a Hold from Berenberg Bank's Kerry Holford in a report issued on May 29. However, on May 30, DBS maintained a Buy rating on Pfizer (NYSE: PFE). The company has a one-year high of $31.54 and a one-year low of $20.92. Currently, Pfizer has an average volume of 53.81M. Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PFE in relation to earlier this year. Most recently, in March 2025, JENNIFER B. DAMICO, the SVP & Controller of PFE sold 3,249.00 shares for a total of $84,373.90.
